Loading...
Prescient Therapeutics Limited
PTX.AX•ASX
Healthcare
Biotechnology
A$0.04
A$-0.00(-8.51%)
Prescient Therapeutics Limited (PTX.AX) Financial Performance & Income Statement Overview
Review Prescient Therapeutics Limited’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
52.89%
↑ 52.89%
Operating Income Growth
27.31%
↑ 27.31%
Net Income Growth
-17.61%
↓ 17.61%
Operating Cash Flow Growth
-19.49%
↓ 19.49%
Operating Margin
-192.44%
↓ 192.44%
Gross Margin
100.00%
↑ 100.00%
Net Profit Margin
-233.95%
↓ 233.95%
ROE
-41.93%
↓ 41.93%
ROIC
-37.16%
↓ 37.16%
Prescient Therapeutics Limited (PTX.AX) Income Statement & Financial Overview
Review Prescient Therapeutics Limited's (PTX.AX) income statement with detailed quarterly and annual figures.
| Metric | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 |
|---|---|---|---|---|
| Revenue | $1.25M | $1.77M | $1.94M | $1.17M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $1.25M | $1.77M | $1.94M | $1.17M |
| Gross Profit Ratio | $1.00 | $1.00 | $1.00 | $1.00 |
| R&D Expenses | $1.71M | $2.92M | $4.05M | $3.77M |
| SG&A Expenses | $2.15M | $2.05M | $1.88M | $1.84M |
| Operating Expenses | $3.86M | $4.97M | $5.92M | $5.61M |
| Total Costs & Expenses | $3.86M | $4.97M | $5.92M | $5.61M |
| Interest Income | $0.00 | $311503.00 | $376074.00 | $321870.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $359.00 | -$327.00 | $1044.00 | $1386.00 |
| EBITDA | -$2.61M | -$3.20M | -$5.56M | -$4.44M |
| EBITDA Ratio | -$2.09 | -$1.81 | -$2.87 | -$3.78 |
| Operating Income | -$2.61M | -$3.20M | -$5.92M | -$5.61M |
| Operating Income Ratio | -$2.09 | -$1.81 | -$3.05 | -$4.78 |
| Other Income/Expenses (Net) | -$1.09M | -$3.19M | -$1.57M | -$849581.00 |
| Income Before Tax | -$3.70M | -$6.39M | -$5.56M | -$5.29M |
| Income Before Tax Ratio | -$2.96 | -$3.60 | -$2.87 | -$4.51 |
| Income Tax Expense | -$1.25M | -$1.77M | -$1.94M | -$1.16M |
| Net Income | -$2.45M | -$4.62M | -$3.62M | -$4.12M |
| Net Income Ratio | -$1.96 | -$2.61 | -$1.87 | -$3.51 |
| EPS | -$0.003 | -$0.006 | -$0.004 | -$0.005 |
| Diluted EPS | -$0.003 | -$0.006 | -$0.004 | -$0.005 |
| Weighted Avg Shares Outstanding | $805.36M | $805.34M | $805.30M | $762.29M |
| Weighted Avg Shares Outstanding (Diluted) | $805.32M | $805.32M | $805.30M | $762.29M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan